Suppr超能文献

GSK-J4 表皮药物靶向 H19/细胞粘附分子通路可抑制前列腺癌的转移进展。

Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer.

作者信息

Pecci Valeria, Troisi Fabiola, Aiello Aurora, De Martino Sara, Carlino Angela, Fiorentino Vincenzo, Ripoli Cristian, Rotili Dante, Pierconti Francesco, Martini Maurizio, Porru Manuela, Pinto Francesco, Mai Antonello, Bassi Pier Francesco, Grassi Claudio, Gaetano Carlo, Pontecorvi Alfredo, Strigari Lidia, Farsetti Antonella, Nanni Simona

机构信息

Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, 00168, Italy.

National Research Council (CNR)-IASI, Rome, Italy.

出版信息

Cancer Cell Int. 2024 Feb 5;24(1):56. doi: 10.1186/s12935-024-03231-6.

Abstract

BACKGROUND

About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression. H19, indeed, acts as transcriptional repressor of cell adhesion molecules affecting the PCa metastatic properties. Here, we investigated the role of H19/cell adhesion molecules circuitry on in vivo PCa experimental tumor growth and metastatic dissemination models.

METHODS

H19 was silenced in luciferase-positive PC-3 and 22Rv1 cells and in vitro effect was evaluated by gene expression, proliferation and invasion assays before and after treatment with the histone lysine demethylase inhibitor, GSK-J4. In vivo tumor growth and metastasis dissemination, in the presence or absence of GSK-J4, were analyzed in two models of human tumor in immunodeficient mice by in vivo bioluminescent imaging and immunohistochemistry (IHC) on explanted tissues. Organotypic Slice Cultures (OSCs) from fresh PCa-explant were used as ex vivo model to test GSK-J4 effects.

RESULTS

H19 silencing in both PC-3 and 22Rv1 cells increased: i) E-cadherin and β4 integrin expression as well as proliferation and invasion, ii) in vivo tumor growth, and iii) metastasis formation at bone, lung, and liver. Of note, treatment with GSK-J4 reduced lesions. In parallel, GSK-J4 efficiently induced cell death in PCa-derived OSCs.

CONCLUSIONS

Our findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy.

摘要

背景

约30%的前列腺癌(PCa)患者会进展为转移性PCa,而这种疾病在很大程度上仍然无法治愈。这一证据凸显了开发创新疗法的必要性。在这个方向上,潜在的研究重点可能是像H19这样的长链非编码RNA(lncRNAs),它们具有关键的生物学功能,并且在癌症中表现出显著的失调。此前,我们发现前列腺癌细胞在促肿瘤雌激素和缺氧联合处理下H19转录下调,这反过来又诱导了E-钙黏蛋白和β4整合素的表达。事实上,H19作为细胞黏附分子的转录抑制因子,影响着前列腺癌的转移特性。在此,我们研究了H19/细胞黏附分子通路在体内前列腺癌实验性肿瘤生长和转移扩散模型中的作用。

方法

在荧光素酶阳性的PC-3和22Rv1细胞中沉默H19,并在用组蛋白赖氨酸去甲基化酶抑制剂GSK-J4处理前后,通过基因表达、增殖和侵袭实验评估体外效应。在免疫缺陷小鼠的两种人肿瘤模型中,通过体内生物发光成像和对移植组织的免疫组织化学(IHC)分析,在有或没有GSK-J4的情况下,分析体内肿瘤生长和转移扩散情况。使用来自新鲜前列腺癌移植组织的器官型切片培养(OSCs)作为体外模型来测试GSK-J4的效果。

结果

PC-3和22Rv1细胞中H19沉默均增加了:i)E-钙黏蛋白和β4整合素的表达以及增殖和侵袭,ii)体内肿瘤生长,iii)在骨、肺和肝的转移形成。值得注意的是,用GSK-J4处理可减少病变。同时,GSK-J4有效地诱导了前列腺癌来源的OSCs中的细胞死亡。

结论

我们的研究结果强调了H19/细胞黏附分子通路作为前列腺癌治疗靶向方法的潜力。调节这种相互作用已被证明可有效抑制肿瘤生长和转移,为靶向治疗提供了合理依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c86e/10845766/a33aa1931b41/12935_2024_3231_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验